SeaStar Medical is a privately held medical technology company that is redefining how extracorporeal therapies can reduce the consequences of excessive inflammation on vital organs through novel solutions and services. Our focus is on transforming key immune system messengers from pro-inflammatory to reparative physiology or removing pro-inflammatory mediators, known as cytokines. The impact of inflammation on organs and long-term health is just beginning to be understood. We have studied the market, assembled the experts to research the science and evaluated the opportunity.
With a new management team, fresh focus and innovative products in development, we invite you to get to know today’s SeaStar Medical.
Eric is a veteran executive with deep experience in deep financial, operational and management experience in healthcare and scientific industries. As a leader of SeaStar Medical, he has restructured and recapitalized the company, repositioned the product offering and expanded its research and development footprint to support and execute company objectives.
Ray is a results-driven leader with vast experience in business and partnership development, operational excellence, global strategic relationships and brand/program management. As Board Chair, he provides a smooth and robust business interface with the board members. He works closely with the team as a trusted advisor to provide strategic insight and support commercial operations.
NxStage Fresenius North America
Dow Chemical Company
SeaStar Medical is fighting the consequences of inflammation in critically ill patients. To learn more about our vision and strategy, please contact us.